• Company
• LDL-C target for cardiovascular dz will be lowered in Korea
• by Apr 25, 2022 06:07am

• Policy
• Expansion of benefit standards such as Tenofovir/Baricitinib
• by Kim, Jung-Ju Apr 24, 2022 06:33pm

• Company
• Samsung BioLogics acquired all of its shares in Epis
• by Chon, Seung-Hyun Apr 24, 2022 06:33pm

• Company
• Tecentriq, first immunotherapy reimbursed in liver cancer
• by jung, sae-im Apr 22, 2022 06:07am

• Company
• The opinions of the pharmaceutical community vary widely
• by jung, sae-im Apr 22, 2022 06:07am

• InterView
• We are making all efforts to reimburse ‘Vyndamax’
• by Eo, Yun-Ho Apr 21, 2022 06:03am

• Opinion
• [Reporter’s View] 1st oral abortion pill approval difficult
• by Lee, Hye-Kyung Apr 21, 2022 06:03am

• Company
• Companies are struggling with the form of post-COVID-19 work
• by Apr 20, 2022 06:06am

• Opinion
• [Reporter’s View] Patience is a virtue...for drugs?
• by Eo, Yun-Ho Apr 20, 2022 06:05am

• Company
• Homegrown Rosuzet·K-CAB sell over ₩10 bil a month
• by Chon, Seung-Hyun Apr 20, 2022 06:05am